Experienced in Virilizing Ovarian Tumor

Dr. Jorge M. Chaves

Tacoma, WA
Experienced
in Virilizing Ovarian Tumor
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Jorge Chaves is a Hematologist Oncology specialist and an Oncologist in Tacoma, Washington. Dr. Chaves and is rated as an Experienced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Large-Cell Immunoblastic Lymphoma, and Mantle Cell Lymphoma (MCL). Dr. Chaves is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Texas Medical School At Houston
Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in WA
Hospital Affiliations
Harrison Medical Center
St Joseph Medical Center
St Anthony Hospital
Languages Spoken
English
Castilian
Filipino
Konkani
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  PacificSource
  •  Premera

Locations

NORTHWEST MEDICAL SPECIALTIES PLLC
1624 S I St, Suite 305, Tacoma, WA 98405
253-428-8700

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Drug
Study Drugs: ZW25, Paclitaxel, Capecitabine, Vinorelbine
Study Phase: Phase 1
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 17, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 16, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

1 Total Publications

A need to monitor P. falciparum resistance to artesunate in Peru
A need to monitor P. falciparum resistance to artesunate in Peru
Journal: Revista peruana de medicina experimental y salud publica
Published: January 23, 2013
Similar Doctors
Expertise in
28
conditions
Dr. Andrea L. Veatch
Hematology Oncology | Oncology | Hematology
Expertise in
28
conditions
Dr. Andrea L. Veatch
Hematology Oncology | Oncology | Hematology

Northwest Medical Specialties PLLC

34509 9th Ave S, Suite 107, 
Federal Way, WA 
 (6.6 mi)
253-428-8700
Languages Spoken:
English, French, Konkani, Malayalam, Spanish, Turkish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrea Veatch is a Hematologist Oncology specialist and an Oncologist in Federal Way, Washington. Dr. Veatch and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Testicular Yolk Sac Tumor, and Virilizing Ovarian Tumor. Dr. Veatch is currently accepting new patients.

Expertise in
87
conditions
Dr. Malcolm W. Winter
Hematology Oncology | Hematology | Oncology
Expertise in
87
conditions
Dr. Malcolm W. Winter
Hematology Oncology | Hematology | Oncology
2720 Clare Ave Ste A, 
Bremerton, WA 
 (25.3 mi)
360-479-6154
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Malcolm Winter is a Hematologist Oncology specialist and a Hematologist in Bremerton, Washington. Dr. Winter and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Paget Disease of the Breast, Chromophobe Renal Cell Carcinoma, and Bone Marrow Aspiration. Dr. Winter is currently accepting new patients.

Expertise in
47
conditions
Dr. Jason C. Comer
Hematology Oncology | Hematology | Oncology
Expertise in
47
conditions
Dr. Jason C. Comer
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (26.8 mi)
206-288-1000
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Comer is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Comer and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Non-Hodgkin Lymphoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Familial Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Comer is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile